jsi-1187
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2020 (NCT04418167)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06239623 | Phase 1 | Apr 2, 2022 | Beijing Cancer Hosptial, JS InnoPharm, LLC |
| NCT04418167 | Phase 1 | Jun 15, 2020 | JS InnoPharm, LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| JS InnoPharm, LLC | For profit | 2 | 2 | 1 | 2020 |
| Beijing Cancer Hosptial | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1